EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Analyst Geoff Meacham from Citi maintained a Hold rating on Regeneron (REGN – Research Report) and decreased the price target to $795.00 from ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful ...

The suit alleges defendants issued false statements concerning Regeneron business and prospects, resulting in its stock trading at inflated prices.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Regeneron Pharmaceuticals, In ...